Herophilus

Herophilus is a private, pre-clinical stage biotech leveraging a proprietary platform of human brain organoids, high-throughput biology, and AI/ML to de-risk and accelerate CNS drug discovery. The company has established a pipeline targeting high-need neurological and psychiatric conditions, including Rett syndrome, Alzheimer's disease, and schizophrenia, starting from a patient-derived biobank. By generating deep phenotypic data from physiologically relevant human models, Herophilus aims to identify novel drug candidates with a greater probability of clinical success.

Integrated platform combining patient-derived human brain organoids, scaled high-throughput biology, and machine learning/AI for systematic neuro drug discovery and de-risking.

Herophilus competes in the emerging field of organoid-based drug discovery, alongside companies like Cerevel (focused on clinical-stage CNS drugs), Heartbeat Health (cardiac organoids), and various AI-driven biotechs (e.g., Recursion, Exscientia). Its specific focus on scaled, AI-integrated human brain organoids for systematic discovery is a differentiating niche.